Selective inhibition of human solute carrier transporters by multikinase inhibitors

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1851-1857

  Johnston, Rosie A ^a   Rawling, Tristan ^b   Chan, Ting ^a   Zhou, Fanfan ^a   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BOSUTINIB; CARRIER PROTEIN; CEDIRANIB; ERLOTINIB; FORETINIB; GEFITINIB; LAPATINIB; N' HYDROXYMETHYLSORAFENIB; N' HYDROXYMETHYLSORAFENIB N OXIDE; N' NORSORAFENIB; N' NORSORAFENIB N OXIDE; NERATINIB; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; SORAFENIB N OXIDE; UNCLASSIFIED DRUG; VANDETANIB; PROTEIN KINASE INHIBITOR;

ARTICLE; COMPETITIVE INHIBITION; DRUG COMPETITION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NUCLEOTIDE SEQUENCE; CELL CULTURE; HEK293 CELL LINE; PHYSIOLOGY;

CARRIER PROTEINS; CELLS, CULTURED; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS;

EID: 84907587051     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059097     Document Type: Article

References (51)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. Chang C, Pang KS, Swaan PW, and Ekins S (2005) Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 314:533-541.
3. Cui Y, König J, Leier I, Buchholz U, and Keppler D (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626-9630.
4. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, and Annaert PP (2013) Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol 83:1257-1267.
5. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, and Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551-603.
6. Erlichman C, Hidalgo M, Boni JP, Martins P, Quinn SE, Zacharchuk C, Amorusi P, Adjei AA, and Rowinsky EK (2006) Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252-2260.
7. Filppula AM, Laitila J, Neuvonen PJ, and Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165:2787-2798.
8. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, and Lum BL (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46:282-290.
9. Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, Edwards RJ, Cui PH, and Murray M (2012) Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem Pharmacol 84:215-223.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
11. Gu R, Hibbs DE, Ong JA, Edwards RJ, and Murray M (2014) The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochem Pharmacol 88:245-252.
12. Gui C, Miao Y, Thompson L, Wahlgren B, Mock M, Stieger B, and Hagenbuch B (2008) Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol 584:57-65.
13. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, and Leighton JK, et al. (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14:5325-5331.
14. Hsyu PH, Mould DR, Upton RN, and Amantea M (2013) Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol 71:209-218.
15. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, and Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATPbinding cassette transporters. Clin Cancer Res 15:6062-6069.
16. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, and Sparreboom A (2008) Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141-3148.
17. Hu S, Mathijssen RH, de Bruijn P, Baker SD, and Sparreboom A (2014) Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 110:894-898.
18. Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, and Wolf J, et al. (2009) Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220-1226.
19. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
20. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, and Sugiyama Y (2013) Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos 41:1859-1866.
21. Kaler G, Truong DM, Khandelwal A, Nagle M, Eraly SA, Swaan PW, and Nigam SK (2007) Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem 282:23841-23853.
22. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, and Artursson P (2012) Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 55: 4740-4763.
23. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, and Kantarjian HM, et al. (2012) Population pharmacokinetic and exposureresponse analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68:723-733.
24. Li J, Brahmer J, Messersmith W, Hidalgo M, and Baker SD (2006) Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 24:291-297.
25. Liu Y, Ramírez J, House L, and Ratain MJ (2010) Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38:32-39.
26. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, and Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci USA 109:18281-18289.
27. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10: 531-539.
28. Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, Büchert M, Unger C, Blum H, Hennig J, and Milenkova TP, et al. (2009) DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 1:5.
29. Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, and LoRusso PM (2012) A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs 30:327-334.
30. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, and Hirose M, et al. (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922-930.
31. Noé J, Portmann R, Brun ME, and Funk C (2007) Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35:1308-1314.
32. Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2004) Functional characterization of pHsensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445.
33. O'Brien Z and Fallah Moghaddam M (2013) Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data. Expert Opin Drug Metab Toxicol 9:1597-1612.
34. Roth M, Obaidat A, and Hagenbuch B (2012) OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165: 1260-1287.
35. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, and Tsuji A (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34: 1423-1431.
36. Scheffler M, Di Gion P, Doroshyenko O, Wolf J, and Fuhr U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 50:371-403.
37. Segel IH (1975) Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, John Wiley & Sons, New York.
38. Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, and Ohtsu A (2010) Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28:866-875.
39. Shitara Y, Takeuchi K, and Horie T (2013) Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci 102:3427-3435.
40. Smith NF, Acharya MR, Desai N, Figg WD, and Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4: 815-818.
41. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, and Wild MJ (2005) Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067-1081.
42. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, and Galitz L, et al. (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197-203.
43. van Erp NP, Gelderblom H, and Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706.
44. Walker AL, Franke RM, Sparreboom A, and Ware RE (2011) Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol 39:446-456.
45. Wind S, Schmid M, Erhardt J, Goeldner RG, and Stopfer P (2013) Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 52:1101-1109.
46. Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, and Ellis MJ, et al. (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558.
47. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, and Tamura T (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496.
48. Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, and Boku N, et al. (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 64: 1165-1172.
49. Zhou F, Lee AC, Krafczyk K, Zhu L, and Murray M (2011) Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 162:1380-1388.
50. Zhou F, Zhu L, Cui PH, Church WB, and Murray M (2010) Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol 159:419-427.
51. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, and Baker SD (2013) Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenibglucuronide. Clin Cancer Res 19:1458-1466.